ES2091689T3 - Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. - Google Patents

Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.

Info

Publication number
ES2091689T3
ES2091689T3 ES94903936T ES94903936T ES2091689T3 ES 2091689 T3 ES2091689 T3 ES 2091689T3 ES 94903936 T ES94903936 T ES 94903936T ES 94903936 T ES94903936 T ES 94903936T ES 2091689 T3 ES2091689 T3 ES 2091689T3
Authority
ES
Spain
Prior art keywords
treatment
application
pct
oxcarbazepine
carbamazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903936T
Other languages
English (en)
Inventor
Alain Boireau
Adam Doble
Pierre Dubedat
Erik Louvel
Mireille Meunier
Jean-Marie Miquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2091689T3 publication Critical patent/ES2091689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

APLICACION DE UN ANTICONVUSIONANTE ELEGIDO ENTRE LA CARBAMACEPINA O LA OXCARBACEPINA O LAS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS DESTINADOS AL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Y DE LOS SINDROMES PARKINSONIANOS.
ES94903936T 1993-01-07 1994-01-03 Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. Expired - Lifetime ES2091689T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Publications (1)

Publication Number Publication Date
ES2091689T3 true ES2091689T3 (es) 1996-11-01

Family

ID=9442862

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94903936T Expired - Lifetime ES2091689T3 (es) 1993-01-07 1994-01-03 Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
ES94903935T Expired - Lifetime ES2092890T3 (es) 1993-01-07 1994-01-03 Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94903935T Expired - Lifetime ES2092890T3 (es) 1993-01-07 1994-01-03 Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.

Country Status (23)

Country Link
US (2) US5658900A (es)
EP (2) EP0678026B1 (es)
JP (2) JPH08505379A (es)
KR (2) KR100298807B1 (es)
AT (2) ATE144420T1 (es)
AU (3) AU677279B2 (es)
CA (2) CA2153340C (es)
CZ (2) CZ284363B6 (es)
DE (2) DE69400435T2 (es)
DK (2) DK0678023T3 (es)
ES (2) ES2091689T3 (es)
FR (1) FR2700117B1 (es)
GR (2) GR3020975T3 (es)
HU (2) HU217136B (es)
IL (3) IL108285A0 (es)
MX (2) MX9307885A (es)
NO (2) NO952310L (es)
PL (2) PL309596A1 (es)
RU (1) RU2221563C2 (es)
SK (2) SK279758B6 (es)
UA (1) UA29464C2 (es)
WO (3) WO1994015610A1 (es)
ZA (3) ZA9426B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
EP1043996A2 (en) * 1998-01-09 2000-10-18 Mor-Research Applications Ltd. Treatment of dyskinesias
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
JP2004526706A (ja) * 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
EP1924326B1 (en) 2005-08-25 2016-10-12 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
AU2006337141A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
DE602007012236D1 (de) * 2006-04-26 2011-03-10 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
BRPI0816784A8 (pt) * 2007-09-14 2016-01-19 Scil Tech Gmbh Fatores neuro-endócrinos para o tratamento de doenças degenerativas
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
WO2011017319A1 (en) * 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
KR102488927B1 (ko) 2016-06-13 2023-01-13 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
WO2021055890A1 (en) * 2019-09-20 2021-03-25 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
HU9502065D0 (en) 1995-09-28
EP0678023A1 (fr) 1995-10-25
HU217136B (hu) 1999-11-29
HU9502063D0 (en) 1995-09-28
NO952309D0 (no) 1995-06-12
ES2092890T3 (es) 1996-12-01
AU684059B2 (en) 1997-12-04
CA2153340C (fr) 2002-12-17
SK86695A3 (en) 1996-05-08
FR2700117B1 (fr) 1995-02-03
EP0678026B1 (fr) 1996-08-28
DE69400435D1 (de) 1996-10-02
MX9307885A (es) 1994-07-29
US5658900A (en) 1997-08-19
WO1994015601A1 (fr) 1994-07-21
UA29464C2 (uk) 2000-11-15
NO307495B1 (no) 2000-04-17
ZA9428B (en) 1994-08-11
JPH08505379A (ja) 1996-06-11
KR960700054A (ko) 1996-01-19
ATE144420T1 (de) 1996-11-15
NO952310D0 (no) 1995-06-12
CZ284928B6 (cs) 1999-04-14
AU5819094A (en) 1994-08-15
IL108286A0 (en) 1994-04-12
WO1994015607A1 (fr) 1994-07-21
EP0678023B1 (fr) 1996-10-23
AU677279B2 (en) 1997-04-17
WO1994015610A1 (fr) 1994-07-21
JPH08505378A (ja) 1996-06-11
KR100298807B1 (ko) 2001-11-22
PL309596A1 (en) 1995-10-30
SK279758B6 (sk) 1999-03-12
DE69400799D1 (de) 1996-11-28
AU5818894A (en) 1994-08-15
SK86795A3 (en) 1995-11-08
DK0678026T3 (da) 1996-09-16
NO952310L (no) 1995-06-12
CZ284363B6 (cs) 1998-11-11
HUT72328A (en) 1996-04-29
NO952309L (no) 1995-06-12
ZA9432B (en) 1994-08-11
IL108284A0 (en) 1994-04-12
PL309594A1 (en) 1995-10-30
DK0678023T3 (da) 1996-11-25
ZA9426B (en) 1994-08-11
CZ176595A3 (en) 1995-12-13
FR2700117A1 (fr) 1994-07-08
DE69400435T2 (de) 1997-03-06
SK279645B6 (sk) 1999-01-11
CA2153341A1 (fr) 1994-07-21
CZ176495A3 (en) 1995-12-13
JP3120153B2 (ja) 2000-12-25
US5674885A (en) 1997-10-07
IL108284A (en) 1999-03-12
AU5818994A (en) 1994-08-15
HUT72074A (en) 1996-03-28
CA2153340A1 (fr) 1994-07-21
DE69400799T2 (de) 1997-03-13
ATE141792T1 (de) 1996-09-15
KR960700059A (ko) 1996-01-19
GR3020975T3 (en) 1996-12-31
EP0678026A1 (fr) 1995-10-25
GR3021438T3 (en) 1997-01-31
IL108285A0 (en) 1994-04-12
MX9400287A (es) 1994-07-29
RU2221563C2 (ru) 2004-01-20

Similar Documents

Publication Publication Date Title
ES2091689T3 (es) Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
NO307204B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter ved behandling av stråleskader

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19960401

FG2A Definitive protection

Ref document number: 678026

Country of ref document: ES